Skip to content

PAtient-PHYsician Relationship Assessment

Evaluation of the Patient-physician Relationship During the Initial Consultation Prior to the Introduction of a New Systemic Treatment for Advanced Hepatocellular Carcinoma: Information Needs, Prognostic Awareness, Treatment Expectations Regarding Efficacy and Side Effects

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05729230
Acronym
PAPHYRA
Enrollment
50
Registered
2023-02-15
Start date
2021-04-05
Completion date
2023-01-31
Last updated
2023-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

systemic treatment

Brief summary

I) Introduction Patients with cancer face difficult choices that require balancing competing priorities such as survival, functional capacity and symptom relief. Most patients with advanced cancer (\>80%) expect frank yet sensitive discussions with their physicians about prognosis and treatment choices in order to be involved in the decision-making process. Nevertheless, this kind of discussion is frequently lacking, and consequently, patients often have a biased view of their own prognosis such as an underestimation of disease severity, or unrealistic expectations for cure. Patients with advanced hepatocellular carcinoma (HCC) may be treated with systemic therapies which may prolong survival but are not curative. Patients with advanced HCC often report expectations for survival and treatment-related side effects that differ from their treating physician. Accordingly, communication on prognostic and treatment choices is essential to obtain an accurate understanding of the disease that allows patients to make informed decisions. To the best of our knowledge, a thorough evaluation of the physician-patient communication quality has never been performed in advanced HCC patients. The aim of our study is to assess the perception of the expected prognosis and treatment side effects by the patient and his physician during the first consultation before the initiation of a new systemic therapy. II) Type of study: Prospective, observational, non-interventional multicentric study III) Outcomes III.1) Primary Outcome Evaluate the concordance between the patient's perception of his prognosis and treatment side effects with the one of his treating physician. III.2) Secondary Outcomes * Compare the patient's expectations for the aforementioned items to those of his physician and the degree of concordance between them. * Evaluation of patient satisfaction with the information received during the consultation * Assessment of patient-reported symptoms of anxiety and depression * Evaluate the association between individual prognosis expectation (i.e., patient and physician) and data from the available literature. IV) Recruitment All consecutive patients with a new systemic treatment prescribed for HCC in participating centres will be included for a period of 1 year.

Detailed description

Patients with cancer face difficult choices that require balancing competing priorities such as survival, functional capacity and symptom relief. Most patients with advanced cancer (\>80%) expect frank yet sensitive discussions with their physicians about prognosis and treatment choices in order to be involved in the decision-making process. Nevertheless, this kind of discussion is frequently lacking, and consequently, patients often have a biased view of their own prognosis such as an underestimation of disease severity, or unrealistic expectations for cure. Patients with advanced hepatocellular carcinoma (HCC) may be treated with systemic therapies which may prolong survival but are not curative. Patients with advanced HCC often report expectations for survival and treatment-related side effects that differ from their treating physician. Accordingly, communication on prognostic and treatment choices is essential to obtain an accurate understanding of the disease that allows patients to make informed decisions. To the best of our knowledge, a thorough evaluation of the physician-patient communication quality has never been performed in advanced HCC patients. The aim of our study is to assess the perception of the expected prognosis and treatment side effects by the patient and his physician during the first consultation before the initiation of a new systemic therapy.

Interventions

BEHAVIORALQuestionnaire

Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease. Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients.

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
CollaboratorOTHER
ASZ Aalst
CollaboratorOTHER
Grand Hôpital de Charleroi
CollaboratorOTHER
AZ Sint-Jan AV
CollaboratorOTHER
CHC Montlegia
CollaboratorOTHER
Erasme University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* diagnose of advanced hepatocellular carcinoma by histology or radiology using the EASL criteria * ≥ 18 years old * willing to participate in the study, being capable of consenting and sign the informed consent * not candidate for curative treatment or locoregional therapy * any line systemic therapy that has been validated by the local hepatic tumor board.

Exclusion criteria

* Locoregional treatment combined with systemic treatment * Pregnancy in progress * Candidate for surgery or locoregional therapy * Patient with state medical aid (AME)

Design outcomes

Primary

MeasureTime frameDescription
Perception of prognosis and treatment side effects12 monthsEvaluate the concordance between the patient's perception of his prognosis and treatment side effects with the one of his treating physician. Use of survey completed by the patient and the doctors to assess the primary endpoint

Secondary

MeasureTime frameDescription
Compare the patient's expectations for the aforementioned items to those of his physician and the degree of concordance between them.12 monthsUse of survey completed by the patient and the doctors to assess the primary endpoint
Assessment of patient-reported symptoms of anxiety and depression12 monthsUse of survey completed by the patient and the doctors to assess the primary endpoint
Evaluate the association between individual prognosis expectation (i.e., patient and physician) and data from the available literature.12 monthsUse of survey completed by the patient and the doctors to assess the primary endpoint
Evaluation of patient satisfaction with the information received during the consultation12 monthsUse of survey completed by the patient and the doctors to assess the primary endpoint

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026